Kymera COO exercises options, sells 22K shares

Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and related stock sales in Kymera common stock.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and related stock sales in Kymera common stock. He exercised stock options covering 22,240 shares at an exercise price of $29.64 per share on March 31 and April 1, 2026, converting derivative positions into common shares.

On the same dates, he sold 22,240 shares of common stock in open-market transactions at weighted average prices between $85.02 and $85.97 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly owns 61,202 shares of Kymera common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 22,240 shares ($1.24M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Chadwick Jeremy G

Role Chief Operating Officer

Sold 22,240 shs ($1.90M)

Approx. gross sale proceeds $1.90M

Approx. exercise cost $659K

Approx. pre-tax spread $1.24M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	14,640	$0.00	$0.00
Exercise	Common Stock	14,640	$29.64	$434K
Sale	Common Stock	13,540	$85.4144	$1.16M
Sale	Common Stock	1,100	$86.05	$95K
Exercise	Stock Option (Right to Buy)	7,600	$0.00	$0.00
Exercise	Common Stock	7,600	$29.64	$225K
Sale	Common Stock	7,600	$85.3792	$649K

Holdings After Transaction: Stock Option (Right to Buy) — 68,633 contracts (Direct); Common Stock — 61,202 shares (Direct)

Footnotes (4)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.02 to $85.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Key Figures

Shares exercised: 22,240 shares Exercise price: $29.64 per share Shares sold: 22,240 shares +4 more

7 metrics

Shares exercised 22,240 shares Stock option exercises on March 31 and April 1, 2026

Exercise price $29.64 per share Stock options on Kymera common stock

Shares sold 22,240 shares Open-market sales on March 31 and April 1, 2026

Sale prices $85.02–$85.97 per share Weighted average price ranges disclosed in footnotes

Shares held after transactions 61,202 shares Direct ownership of Kymera common stock following April 1, 2026

Option expiration May 22, 2033 Expiration date for the reported stock options

Option vesting start May 22, 2024 25% of option vested then; remainder monthly over 36 months

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +2 more

6 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

vesting financial

"shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kymera (KYMR) COO Jeremy Chadwick report?

Kymera COO Jeremy Chadwick exercised stock options for 22,240 shares and sold 22,240 common shares. The trades occurred on March 31 and April 1, 2026, converting options into stock and then liquidating an equivalent number of shares in open-market transactions.

At what prices did the Kymera (KYMR) COO sell his shares?

The Kymera COO sold shares at weighted average prices between about $85.02 and $85.97 per share. Individual trades occurred within this range, with specific prices including $85.3792, $85.4144 and $86.05, as disclosed in the transaction details and accompanying footnotes.

How many Kymera (KYMR) shares does the COO hold after these trades?

After completing the option exercises and related sales, the Kymera COO directly holds 61,202 shares of common stock. This figure reflects his post-transaction ownership reported in the Form 4 and provides context for the scale of the exercised and sold amounts.

Were the Kymera (KYMR) COO’s stock sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans are pre-arranged schedules for trading, designed to allow insiders to sell shares over time under predetermined instructions.

What was the exercise price of the Kymera (KYMR) stock options?

The exercised Kymera stock options had an exercise price of $29.64 per share. The COO converted options into 22,240 common shares at this price across March 31 and April 1, 2026, before selling an equivalent number of shares in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chadwick Jeremy G

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		M(1)		7,600	A	$29.64	68,802	D
Common Stock	03/31/2026		S(1)		7,600	D	$85.3792(2)	61,202	D
Common Stock	04/01/2026		M(1)		14,640	A	$29.64	75,842	D
Common Stock	04/01/2026		S(1)		13,540	D	$85.4144(3)	62,302	D
Common Stock	04/01/2026		S(1)		1,100	D	$86.05	61,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$29.64	03/31/2026		M(1)			7,600	(4)	05/22/2033	Common Stock	7,600	$0	83,273	D
Stock Option (Right to Buy)	$29.64	04/01/2026		M(1)			14,640	(4)	05/22/2033	Common Stock	14,640	$0	68,633	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.02 to $85.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)